Aditxt, Inc. (OTCPK: ADTX)
Health Care · Biotechnology · US
$0.01
+117.39% today · -100.0% 1Y
Aditxt, Inc. (OTCPK: ADTX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $4.08K and employs 26 people.
Over the last twelve months the share price has lost 100.0%, trading between 0.00 and 117.84.
Tweenvest scores Aditxt, Inc. across four factors: quality 5/100. Its strongest factor is quality.
ADTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.08K
- Revenue (TTM)
- $14.34K
- P/E
- —
- EPS
- -1,380.76
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $117.84
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 815.92K
- Employees
- 26
- Next earnings
- —
About Aditxt, Inc.
Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques. The company's developments include AditxtScore, a platform designed to empower individuals by providing insights into their immune profiles for better management and informed awareness of immune system attacks or dysfunctions. Aditxt also pioneers Apoptotic DNA Immunotherapy, a nucleic acid-based solution that emulates the body's inherent mechanisms for developing self-tolerance to its own tissues. Additionally, Aditxt is actively researching and developing ADi products with diverse therapeutic applications, such as for organ transplant procedures (including skin grafting), various autoimmune conditions, and allergic reactions. The company holds licensing agreements with esteemed institutions like Loma Linda University and Leland Stanford Junior University. Established in 2017, this Richmond, Virginia-headquartered company was initially known as ADiTx Therapeutics, Inc. before rebranding to Aditxt, Inc. in July 2021.
- ISIN
- US0070258696
- Founded
- 2017
- Listed since
- Jun 30, 2020
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.53 | -1.60% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $440.95 | -0.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $147.78 | -0.67% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $548.74 | -0.74% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $827.02 | -0.78% |
| argenx SEENXTBR: ARGX | $64.17B | €895.40 | +1.84% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $155.61 | -2.03% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.